$AQST

AQUESTIVE THERAPEUTICS, INC. (AQST) SHAREHOLDER ALERT

Bernstein Liebhard LLP reminds investors of Aquestive Therapeutics, Inc. (AQST) about an upcoming deadline in a securities fraud class action lawsuit. Investors who purchased shares between June 16, 2025, and January 8, 2026, and lost money, are encouraged to contact the firm by May 4, 2026, to discuss their legal options, including serving as lead plaintiff. The lawsuit alleges that Aquestive made misrepresentations regarding its New Drug Application for Anaphylm.

Original reporting
GlobeNewswire · Bernstein Liebhard LLP
Published Mar 27, 2026, 12:40 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 27, 2026, 1:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AQUESTIVE THERAPEUTICS, INC. (AQST) SHAREHOLDER ALERT — source image
Decision brief

The 30-second read

$AQSTBearishHigh
01

Why it matters

Legal proceedings could result in financial penalties, stock price volatility, and reputational damage, affecting investor confidence.

02

Market read

The lawsuit's allegations directly impact AQST's stock and investor sentiment, with potential sector-wide implications for biotech firms under legal scrutiny.

03

What to watch

Company's underlying drug pipeline and recent clinical trial results may offset legal concerns if they demonstrate strength.

Timing: Immediate; news published on 2026-03-27 is recent and relevant for trading decisions today.

Background

This news pertains to a securities fraud class action lawsuit against Aquestive Therapeutics, alleging misrepresentation regarding its NDA for Anaphylm.

Company-level read

Ticker impact

$AQSTBearishHigh confidence
Context

High relevance due to direct involvement in securities fraud lawsuit affecting investor confidence.

Expected impact

Potential short-term decline of 10-15% following news release, with possible stabilization depending on legal proceedings.

Evidence & confidence

Legal actions and allegations of misrepresentation typically lead to immediate negative market reactions, especially when involving investor losses.

Market effects

Potential negative impact on the biotech and life sciences sectors due to legal and regulatory concerns.

Limited regional impact; primarily affects US-based biotech stocks.

Moderate; legal issues in biotech can influence global investor sentiment towards similar companies.

Counterpoint

Legal allegations may be unfounded or exaggerated; potential for positive resolution could lead to recovery.

Key entities

  • Aquestive Therapeutics, Inc.

    Biotech company involved in developing and commercializing pharmaceutical products.

  • Bernstein Liebhard LLP

    Legal firm representing investors in the class action lawsuit.

Related articles

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.

$LMTMed

Pentagon pushes military contractors to accelerate production amid shortages after war on Iran

The Pentagon ordered US defense contractors to submit within 21 days plans to accelerate production of missiles and interceptors amid shortages after the first month of strikes against Iran. It cited depleted Patriot and THAAD inventories and said framework agreements with Lockheed Martin and Northrop Grumman target PAC-3 and THAAD output. Lockheed Martin received a contract up to $58.6B to triple PAC-3 production by 2030.

$NOCMed

WP: Pentagon asks defense companies to urgently ramp up weapons production

The Pentagon, via Deputy Secretary Steve Feinberg, urged U.S. defense firms to accelerate weapons output, especially ammunition, and asked executives to submit production and delivery plans within 21 days, according to The Washington Post. CSIS data cited Patriot and THAAD stockpiles falling sharply. The article notes talks with Northrop Grumman and Lockheed Martin and a Lockheed contract up to $58.6B to triple PAC-3 output by 2030.